Evidence map›Paper›PMID 42717274›Full record

ArticleGenes, chromosomes & cancer2026

IRF8 Suppresses Hepatocellular Carcinoma Progression Through LIAS-Dependent IFN Production and Cuproptosis Activation.

Li Zhu, Zhaoxia Hu, Bei Wu, Meng Duan, Li Wang, Ruiqing Hu, Hongfan Liao, Xiaosi Zhao, Yilan Zeng, Lei Li and 2 more

Abstract read
In one paragraph

Article in Genes, chromosomes & cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Li ZhuSecond Department of Hepatology, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China.
Zhaoxia HuSecond Department of Hepatology, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China.
Bei WuSecond Department of Hepatology, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China.
Meng DuanSecond Department of Hepatology, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China.
Li WangSecond Department of Hepatology, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China.
Ruiqing HuSecond Department of Hepatology, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China.
Hongfan LiaoSecond Department of Hepatology, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China.
Xiaosi ZhaoSecond Department of Hepatology, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China.
Yilan ZengSecond Department of Hepatology, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China.
Lei LiXiamen AMOYTOP Biotech Co, Ltd., Xiamen, People's Republic of China.
Yuelian WangDepartment of Integrated Traditional Chinese and Western Medicine, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China.
Mei LuoCenter for Precision and Translational Medicine, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China.ORCID https://orcid.org/0009-0009-3972-5387

Funding

Chengdu Medical Research Project 2025563Chengdu Medical Research Project 2025584National Inheritance Studio for Famous & Senior Experts of Traditional Chinese Medicine NATCM Personnel & Education Dept. Letter [2022] No. 75
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide. Cuproptosis is a novel form of regulated cell death closely linked to tumor progression. Although interferon regulatory factors (IRFs) exert tumor-suppressive effects in various cancers, its precise regulatory mechanisms concerning cuproptosis in HCC remain largely elusive.

methodsIRF8 expression was evaluated in clinical HCC specimens and cell lines. Gain- and loss-of-function assays were conducted. Underlying transcriptional mechanisms were elucidated using ChIP-qPCR and dual-luciferase reporter assays. Subcutaneous nude mouse xenograft models were utilized to validate in vivo phenotypes.

resultsIRF8 was significantly downregulated in HCC. IRF8 overexpression induced oxidative stress and cuproptosis, as evidenced by excessive intracellular copper accumulation, elevated reactive oxygen species (ROS), and lipid peroxidation. Mechanistically, IRF8 directly bound to the promoter region of lipoyl synthase (LIAS) to activate its transcription. Phenotypic rescue assays confirmed that LIAS is indispensable for IRF8-induced interferon (IFN-α/β) production, copper engorgement, and cuproptosis. Furthermore, in vivo xenograft models demonstrated that IRF8 profoundly impeded tumor growth, an effect that was effectively abrogated by LIAS silencing.

conclusionIRF8 inhibits HCC progression by directly upregulating LIAS to instigate lethal cuproptosis and interferon responses. The IRF8/LIAS axis may serve as a potential mechanistic basis and candidate axis for developing HCC therapeutic strategies.

Indexed as

Carcinoma, HepatocellularCuproptosisInterferon Regulatory FactorsInterferonsLiver NeoplasmsAnimalsCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHumansInterferon Regulatory Factor-8MaleMiceMice, NudeInterferon Regulatory Factor-8Interferon Regulatory FactorsInterferonscuproptosishepatocellular carcinomainterferonIRF8LIAS

Identifiers

PMID42717274
PMCPMC13558782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.